Role of glucagon in protein catabolism
暂无分享,去创建一个
[1] G. Van den Berghe,et al. Amino acid supplements in critically ill patients , 2017, Pharmacological research.
[2] J. Holst,et al. Role of Glucagon in Catabolism and Muscle Wasting of Critical Illness and Modulation by Nutrition , 2017, American journal of respiratory and critical care medicine.
[3] G. Van den Berghe,et al. The Role of Autophagy in Critical Illness-induced Liver Damage , 2017, Scientific Reports.
[4] T. Lange,et al. Early goal-directed nutrition versus standard of care in adult intensive care patients: the single-centre, randomised, outcome assessor-blinded EAT-ICU trial , 2017, Intensive Care Medicine.
[5] J. Gunst. Recovery from critical illness-induced organ failure: the role of autophagy , 2017, Critical Care.
[6] G. Van den Berghe,et al. Effect of early supplemental parenteral nutrition in the paediatric ICU: a preplanned observational study of post-randomisation treatments in the PEPaNIC trial. , 2017, The Lancet. Respiratory medicine.
[7] J. Holst,et al. Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver–α-Cell Axis , 2017, Diabetes.
[8] G. Berghe. On the Neuroendocrinopathy of Critical Illness. Perspectives for Feeding and Novel Treatments. , 2016 .
[9] L. Cynober,et al. Indications and contraindications for infusing specific amino acids (leucine, glutamine, arginine, citrulline, and taurine) in critical illness , 2016, Current opinion in clinical nutrition and metabolic care.
[10] G. Van den Berghe. On the Neuroendocrinopathy of Critical Illness. Perspectives for Feeding and Novel Treatments. , 2016, American journal of respiratory and critical care medicine.
[11] C. Cummins,et al. Glucocorticoids and Metabolic Control. , 2016, Handbook of experimental pharmacology.
[12] A. Scheen,et al. Inhibiting or antagonizing glucagon: making progress in diabetes care , 2015, Diabetes, obesity & metabolism.
[13] O. Fiehn,et al. Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass. , 2015, Cell reports.
[14] R. Bellomo,et al. Intravenous amino acid therapy for kidney function in critically ill patients: a randomized controlled trial , 2015, Intensive Care Medicine.
[15] D. D’Alessio,et al. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. , 2015, Physiological reviews.
[16] A. Groeneveld,et al. Metabolic response to the stress of critical illness. , 2014, British journal of anaesthesia.
[17] J. Holst,et al. Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? , 2014, Diabetologia.
[18] G. Van den Berghe,et al. Effect of tolerating macronutrient deficit on the development of intensive-care unit acquired weakness: a subanalysis of the EPaNIC trial. , 2013, The Lancet. Respiratory medicine.
[19] G. Van den Berghe,et al. Impact of early parenteral nutrition on metabolism and kidney injury. , 2013, Journal of the American Society of Nephrology : JASN.
[20] D. Cook,et al. A randomized trial of glutamine and antioxidants in critically ill patients. , 2013, The New England journal of medicine.
[21] G. Van den Berghe,et al. Role of disease and macronutrient dose in the randomized controlled EPaNIC trial: a post hoc analysis. , 2013, American journal of respiratory and critical care medicine.
[22] G. Van den Berghe,et al. Early parenteral nutrition evokes a phenotype of autophagy deficiency in liver and skeletal muscle of critically ill rabbits. , 2012, Endocrinology.
[23] S. Bloom,et al. Minireview: Glucagon in stress and energy homeostasis. , 2012, Endocrinology.
[24] A. Cherrington,et al. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. , 2012, The Journal of clinical investigation.
[25] N. Ozaki,et al. Remodeling of Hepatic Metabolism and Hyperaminoacidemia in Mice Deficient in Proglucagon-Derived Peptides , 2011, Diabetes.
[26] P. Lefèbvre. Early milestones in glucagon research , 2011, Diabetes, obesity & metabolism.
[27] M. Tschöp,et al. The metabolic actions of glucagon revisited , 2010, Nature Reviews Endocrinology.
[28] Teresa Pearson,et al. Glucagon as a Treatment of Severe Hypoglycemia , 2008, The Diabetes educator.
[29] G. Shepherd. Treatment of poisoning caused by β-adrenergic and calcium-channel blockers , 2006 .
[30] J. Holst,et al. Immunoneutralization of Endogenous Glucagon Reduces Hepatic Glucose Output and Improves Long-Term Glycemic Control in Diabetic ob/ob Mice , 2006, Diabetes.
[31] G. Shepherd. Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[32] The effect of intraportal and peripheral infusions of glucagon on insulin and glucose concentrations and glucose tolerance in normal man , 1977, Diabetologia.
[33] Bei B. Zhang,et al. Glucagon and regulation of glucose metabolism. , 2003, American journal of physiology. Endocrinology and metabolism.
[34] W. Druml,et al. Amino acid kinetics in patients with sepsis. , 2001, The American journal of clinical nutrition.
[35] K. Nair,et al. Evidence for a catabolic role of glucagon during an amino acid load. , 1996, The Journal of clinical investigation.
[36] D. Wynick,et al. Glucagonoma syndrome. , 1987, The American journal of medicine.
[37] J. Holst,et al. Glucagon Immunoneutralization in Diabetic Rats Normalizes Urea Synthesis and Decreases Nitrogen Wasting , 1992, Diabetes.
[38] O. Owen,et al. Glucagon deficiency and hyperaminoacidemia after total pancreatectomy. , 1980, The Journal of clinical investigation.
[39] L. Orci,et al. THE ESSENTIAL ROLE OF GLUCAGON IN THE PATHOGENESIS OF DIABETES MELLITUS , 1975, The Lancet.
[40] S. Bloom,et al. A glucagonoma syndrome. , 1974, Lancet.
[41] J. B. Collip,et al. Pancreatic Extracts in the Treatment of Diabetes Mellitus: Preliminary Report. , 1962, Canadian Medical Association journal.
[42] O. Behrens,et al. The Amino Acid Sequence of Glucagon. II. The Hydrolysis of Glucagon with Chymotrypsin , 1957 .